Triptorelin

Drug Profile

Triptorelin

Alternative Names: ARVEKAP; AY 25650; BIM 21003; BN 52014; CL 118532; Debio 8206; Debio 8206 CPP; Debio 8206 SC; Decapeptyl; Decapeptyl SR; Diphereline; Moapar; Pamorelin; Pamorelin LA; Salvacyl; Trelstar; Trelstar Depot; Triptodur; Triptorelin acetate; Triptorelin embonate; Triptorelin pamoate; Triptoreline; Tryptorelin; WY 42422

Latest Information Update: 05 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tulane University
  • Developer Allergan; Arbor Pharmaceuticals; Debiopharm; European Organisation for Research and Treatment of Cancer; Ipsen; Orient Europharma; Pfizer; United Laboratories
  • Class Antineoplastics; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
  • Mechanism of Action Gonadotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precocious puberty
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Endometriosis; Female infertility; Paraphilias; Precocious puberty; Prostate cancer; Uterine leiomyoma
  • Phase II Salivary gland cancer

Most Recent Events

  • 03 Oct 2017 Launched for Precocious puberty in USA (IM)
  • 01 Aug 2017 Ipsen plans a phase III trial of two formulations of Triptorelin for Endometriosis in China in August 2017 (NCT03232281)
  • 28 Jul 2017 Phase-III clinical trials in Endometriosis in China (IM) (NCT03232281)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top